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Alzheimer diseaseThirteen 2-oxazine-based small molecules were synthesized targeting 5-lipoxygenase (LOX), and
acetylcholinesterase (AChE). The test revealed that the newly synthesized compounds had potent
inhibition towards both 5-LOX and AChE in lower micro molar concentration. Among the tested
compounds, the most active compound, 2-[(2-acetyl-6,6-dimethyl-4-phenyl-5,6-dihydro-2H-1,2-oxa-
zin-3-yl)methyl]-1H-isoindole-1,3(2H)-dione (2a) showed inhibitory activity towards 5-LOX and AChE
with an IC50 values of 1.88, and 2.5 lM, respectively. Further, the in silico molecular docking studies
revealed that the compound 2a bound to the catalytic domain of AChE strongly with a highest CDOCKER
score of 1.18kcal/mol when compared to other compounds of the same series. Additionally, 2a showed
a good lipophilicity (logP = 2.66), suggesting a potential ability to penetrate the blood–brain-barrier.
These initial pharmacological data revealed that the compound 2a could serve as a drug-seed in developing
anti-Alzheimer’s agents.
 2014 Elsevier Ltd. All rights reserved.Alzheimer’s disease (AD) is a progressive age related neurode- protein are considerably up-regulated in affected areas of AD
generative disorder and it is clinically characterized by impairment
in memory, visuospatial skills, complex cognition, language,
emotion and personality. Although the exact cause of AD remains
elusive, mounting evidence continues to support the involvement
of inﬂammation in the development of AD.1 An inﬂammatory
marker, interleukin-1 known to play a major role in enhancing
the neuronal acetylcholinesterase (AChE) activity.2–4 These physio-
logical mechanism or systemic inﬂammation process is termed
‘cholinergic anti-inﬂammatory pathway’ because is mediated by
the neurotransmitter acetylcholine (ACh).5 Based on the compel-
ling evidence that inﬂammatory processes are involved in the
pathogenesis of AD, research has looked into the use of anti-
inﬂammatory drugs as a treatment option for patients with AD.
Epidemiological evidence continues to build up indicating that
non-steroidal anti-inﬂammatory drugs (NSAIDs) may lower the
risk of developing AD.6 A possible mode of action for the effective-
ness of NSAIDs is by the blockage of cyclooxygenase (COX)-2 in the
brain.7–10 Evidently, it has been shown that COX-2 mRNA andbrain,11–13 suggesting the involvement of COX-2 in AD. So, we
herein attempted to design and synthesize, 1,2-oxazine-based small
molecules that could show anti-inﬂammatory activity and also play
a major role in inhibiting the AChE activity that involved in AD. Since
the discovery of 2-amino-1,3-oxazine scaffold was identiﬁed as the
selective and better inhibitors of b-site amyloid precursor protein
cleaving enzyme 1, and also projected to be the suitable starting
point for further development of brain penetrating compounds
for potential Alzheimer’s disease treatment.14 In addition, the
neuroprotective effect of 2-ethoxy-4,5-diphenyl-1,3-oxazine-6-one
against H2O2-induced cell death in rat pheochromocytoma cells
was reported.15 Evidently, the design, synthesis and results on 1,
4-oxazines revealed that the oxazine-based small molecules signiﬁ-
cantly inhibited the transthyretin (TTR) amyloid ﬁbril formation.16
In continuation of our effort to synthesize novel anti-inﬂammatory17
and anti-cholinergic agents,18 we herein report the synthesis,
characterization, anti-inﬂammatory and anti-cholinergic activity of
novel 1,2-oxazine-based small molecules for the ﬁrst time.
A library of racemic tetrasubstituted functionalized 1,2-oxazines
(5,6-dihydro-4H-1,2-oxazines 1 and N-acetyl-5,6-dihydro-2H-1,
2-oxazines 2) required for the biological assays was generated
according to the synthetic strategy previously developed by
us19,20 (Scheme 1, Table 1). Stereoselective assembly of 1,2-oxazine05.040
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Scheme 1. Synthesis of 3,4,5,6-tetrasubstituted-1,2-oxazine-based small mole-
cules. Reagents and conditions: (i) SnCl4, CH2Cl2, 94 C to 30 C; (ii) (CH3)3SiBr,
Et3N, CH2Cl2, 30 C, 24 h; (iii) potassium phthalamide, DMF, 50–60 C, 2 h; (iv)
CH2(CO2CH3)2, KOtBu, DMF, 60 C, 2 h; (v) 15 bar CO/Pd(PPh3)2Cl2, CH3OH, 100 C,
3 h; (vi) AcBr, Ac2O, CH2Cl2, rt, 2 h.
Table 1
Synthesis of 3,4,5,6-tetrasubstituted-1,2-oxazine-based small molecules
Entry R1 R2 R3 R4
1a C6H5 H CH3 CH
1b 4-CH3O–C6H4– H CH3 CH
1c 4-CH3O–C6H4– –(CH2)4– H
1d C6H5 –(CH2)3– H
1e C6H5 H
1f CH3 H CH3 CH
1g 4-CH3O–C6H4– H CH3 CH
1h C6H5 –(CH2)4– H
1i C6H5 H
2a C6H5 H CH3 CH
2b 4-CH3O–C6H4– H CH3 CH
2c C6H5 H CH3 CH
2d 4-Cl–C6H4– H CH3 CH
a Yield for the last step (average of two experiments).
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Please cite this article in press as: Sukhorukov Alexey Yu..; et al. Bioorg. Mcore was achieved by inverse electron demand Diels–Alder (IED-
DA) reaction of nitroalkenes derived from nitroethane to oleﬁnes.
The resulting diastereomerically pure 1,2-oxazine-N-oxides 3were
subjected to silylation with an excess of trimethylsilyl bromide in
the presence of Et3N to give 3-bromomethyl-substituted 5,6-dihy-
dro-4H-1,2-oxazines 4, which serve as key precursors for the syn-
thesis of C-3 functionalized 1,2-oxazines 1 and 2. Thus,
nucleophilic substitution of bromide for phthalimide or dimethyl-
malonate anions furnished 1,2-oxazines 1a–f. 1,2-Oxazines 1g–i
with FG = CO2CH3 were obtained by catalytic carbonylation of cor-
responding bromides 3 in methanol being followed our previously
reported protocol.21 Transformation of 5,6-dihydro-4H-1,2-oxa-
zines 1 into and N-acetyl-5,6-dihydro-2H-1,2-oxazines 2 was
achieved by acetylation of the former with AcBr/Ac2O mixture in
high yields (Scheme 1).
All compounds were obtained in analytically pure form by col-
umn chromatography on silica gel and crystallization. The structure
and stereochemistry of previously unknown products was
conﬁrmed by 1D and 2D NMR spectroscopy and elemental analysis.
Effect of 2-oxazines on LOX-5 and AChE. Oxazin-2-thione-based
small molecule exhibited LOX and COX-1 inhibitory action.22 In
particular, 5-LOX catalyses the biosynthesis of leukotrienes play a
pivotal role in inﬂammatory and allergic disorders as well as in car-
diovascular diseases and cancer.23 Additionally, tetrahydro-1,4-FG Yielda (%) Melting point
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Table 3
CDOCKER Energies of 3,4,5,6-tetrasubstituted-1,2-oxazine small molecules
Compounds -CDOCKER energy
(kcal/mol)
-CDOCKER interaction energy
(kcal/mol)
1a 17.6109 43.3683
1b 46.4932 57.429
1c 37.026 52.236
1d 31.4987 48.0747
1e 39.8809 47.9319
1f 30.7859 33.7126
1g 35.6327 42.8039
1h 28.9761 41.6439
1i 11.8795 44.2924
2a 1.14435 45.1691
2b 25.3233 53.8689
2c 20.7983 51.7264
2d 30.7952 57.8437
Table 2
5-LOX, and AChE inhibitory potential of 3,4,5,6-tetrasubstituted-1,2-oxazine-based
small molecules
Compounds IC50 5-LOX (lM) IC50 AChE (lM)
1a 30.04 65.32
1b 66.87 NSa
1c 33.75 NS
1d 81.68 75.35
1e 21.09 NS
1f NS NS
1g NS NS
1h 16.09 35.12
1i 16.68 6.3
2a 1.88 2.5
2b 1.23 14.35
2c 6.32 12.0
2d NS 46.76
NEOSTIGMINE 2.4
a NS: not signiﬁcant.
A. Yu. Sukhorukov et al. / Bioorg. Med. Chem. Lett. xxx (2014) xxx–xxx 3oxazines are known to be biologically active against inﬂammatory
drug metabolizing enzymes.24 The potential of all the synthesized
compounds to inhibit 5-LOX and AChE was determined on pure
enzymes. Since inﬂammation occurs in the pathological regions
of Alzheimer’s disease (AD) brain, and a few animal models and
clinical studies clearly suggest that AD inﬂammation signiﬁcantly
contributes to AD pathogenesis.1 Some of the tested 1,2-oxazinesFigure 1. Stereoview of the interaction map of compound 2a that bound to the active site
color) of the key amino acids that are interacting with compound 2a (ball and stick mo
Please cite this article in press as: Sukhorukov Alexey Yu..; et al. Bioorg. Mexhibited 5-LOX inhibitory activity, with the exception of 1f, 1g,
and 2d. Amongst the new compounds 2a, 2b, and 2c exhibited
most potent 5-LOX inhibitory activities, whereas compounds 2a
and 1i were found to inhibit the activity of AChE (Table 3)
effectively. Interestingly, the most active compound 2a showed
inhibitory activity towards both the enzymes 5-LOX and AChE with
an IC50 values of 1.88, and 2.5 lM, respectively. These results
indicated that the 1,2-oxazine pharmacophore plays an important
role in deciding the preferences for these enzyme sites. The present
work thus conﬁrms that the 1,2-oxazine-based ligands are effec-
tive LOX/AChE inhibitors, which can serve as promising therapeu-
tic agents against Alzheimer disease.
Structure based in silico molecular docking analysis on 1,2-oxa-
zine-based small molecules that target AChE. Many cholinesterase
inhibitors are used for symptomatic treatment of AD.25 The drug,
Aricept (E2020) was known to enhance performance in animal
models of cholinergic hypofunction and has a high afﬁnity for
AChE.26 Prior to the elucidation of three-dimensional structure of
Torpedo californica AChE (TcAChE), E2020 was designed on the
basis of QSAR studies, which inhibited both electric eel and mouse
AChE in the nanomolar range. Later, the co-crystal structure of the
E2020–TcAChE complex at 2.5 Å resolution (PDB ID: 1EVE) was
reported. This structure was taken for our molecular docking
studies.26 The molecular docking studies on 1,2-oxazine-based
small molecules into the crystal structure of tcAChE were
performed using CDOCKER of Accelrys as reported earlier.27 Out
of 10 docked complexes, the high score of CDOCKER energy was
selected and described (Table 3). The analysis of the molecular
docking revealed that the compound 1i, and 2a bound to the active
site of the tcAChE with a greater extent of CDOCKER energies of
11.8, and 1.14 (kcal/mol), when compared to other structurally
compounds (Table 2). E2020 that bound to the active site of AChE
is compared with the 1,2-oxazines. The binding of compound 2a
towards the binding of AChE is depicted in Figure 1. The compound
2a makes primary interactions at the active-site gorge of the
enzyme through its three major functional groups such as phthal-
amide moiety, N-acetyl-2-oxazine ring, and the phenyl rings. These
functional groups responsible for three inter-hydrogen bonding
formation between Tyr334, Asp72, and Asn85 amino acids,
Gly118, and Ser122 amino acids, and also with Gln69, Gly123,
and Tyr121 amino acids. These results indicate that the strong
afﬁnity of compound 2a on AChE could lead to the potent inhibi-
tion of the catalytic activity of the enzyme.of AChE (PDB ID: 1EVE). The stick model (carbon-pink and other atoms are in parent
del, carbon-green and other atoms are in parent color) was shown.
ed. Chem. Lett. (2014), http://dx.doi.org/10.1016/j.bmcl.2014.05.040
4 A. Yu. Sukhorukov et al. / Bioorg. Med. Chem. Lett. xxx (2014) xxx–xxxWe herein report the synthesis of new 2-oxazine-based small
molecules targeting 5-LOX and AChE. Among the tested com-
pounds, the most active compound 2a showed inhibitory activity
towards 5-LOX and AChE with an IC50 value of 1.88, and 2.5 lM,
respectively. Further, the in silico molecular docking studies
revealed that the compound 2a and 1e bound to the catalytic
domain of AChE strongly with a highest CDOCKER score about
1.18, and 11.8 (kcal/mol), when compared to other compounds
of the same series. These initial pharmacological data revealed that
the compound 2a could serve as a drug-seed in developing anti-
Alzheimer’s agents.
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